Please provide your email address to receive an email when new articles are posted on . Vadadustat demonstrated the efficacy and cardiovascular safety for the treatment of anemia in adult patients ...

DUBLIN--(BUSINESS WIRE)--The "Darbepoetin Alfa (Aranesp) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global darbepoetin alfa (Aranesp) market is expected ...

In separate active comparator studies, roxadustat achieved hemoglobin correction in CKD patients and maintained hemoglobin within target range in hemodialysis patients at least as well as darbepoetin ...

Please provide your email address to receive an email when new articles are posted on . Vadadustat is noninferior to darbepoetin alfa in preserving hemoglobin levels in patients with ...

Poor CVD Drug Adherence Before Dialysis Predicts Worse Survival The new evidence further supports development of the investigational HIF-PHI, which recently also demonstrated noninferiority to ...

In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy. Specific factors may predict better initial response to darbepoetin alfa in patients ...

Cipla collaborates with Hetero to launch its second biosimilar drug 'Darbepoetin alfa' ~Patients with chronic kidney disease and anaemia set to gain~ India, Mumbai, 19th June 2014: Cipla, a global ...

Pilot study to determine the effects of dronabinol on hot flash relief in breast cancer patients Background: Anemia occurring in cancer patients undergoing Chemotherapy and or Radiotherapy causes ...

Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia ...

The studies compared the efficacy and safety of vadadustat to darbepoetin alfa in adult patients on dialysis with anemia due to CKD. Positive topline data were announced from the global phase 3 INNO 2 ...

The FDA previously updated the boxed warning for all erythropoiesis-stimulating agents (darbepoetin [Aranesp], epoetin alfa (Epogen, Procrit]) because of increased risk of serious and life-threatening ...